Sign In

Emil Kakkis

Chief Executive Officer and President at Ultragenyx Pharmaceutical Inc.

Emil Kakkis is a renowned figure in the field of rare disease treatment, with a strong background in biochemistry, medicine, and research. Throughout his career, he has successfully developed and obtained FDA approval for three medicines for rare disease patients, with an additional three in clinical studies.

Emil Kakkis is deeply committed to improving the regulatory process that governs the development of treatments for rare diseases. In 2010, he founded Ultragenyx Pharmaceutical Inc. where he currently serves as the Chief Executive Officer and President. Under his leadership, the company has embarked on multiple clinical programs, with four products and five clinical programs expected in the current year, boasting a team of approximately 70 professionals.

Specializing in drug development for rare diseases and biochemical genetic disease treatment, Emil Kakkis' expertise extends to the clinical management of mucopolysaccharidoses. His dedication to treating untreated rare diseases is evident in Ultragenyx Pharmaceutical Inc.'s mission to swiftly translate therapies for those in need.

Emil Kakkis pursued his education at the University of California, Los Angeles, where he studied MD/PhD in biological chemistry. He also holds a Bachelor of Arts (B.A.) in Biology from Pomona College.

In addition to his role at Ultragenyx Pharmaceutical Inc., Emil Kakkis has held significant positions in various organizations. He has served as the President at EveryLife Foundation for Rare Diseases, a Development Consultant at BioMarin, a Board Member at the National Organization for Rare Disorders, and Chief Medical Officer at BioMarin, among others. Earlier in his career, he was also an Assistant Professor at Harbor-UCLA Research and Education Institute as well as Harbor UCLA Med Center, Research and Education Institute.

E
Add to my network

Location

Novato, California, United States